Bremelanotide (Vyleesi / PT-141): The FDA-Approved Melanocortin Peptide for HSDD

Most peptides discussed in clinical and compounding conversations sit outside FDA-approved indications. Bremelanotide is different. Marketed as Vyleesi, it is a cyclic heptapeptide melanocortin receptor agonist with a specific U.S. indication: treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. In research and grey-market channels the same active moiety is still widely called PT-141.

For clinicians, that dual identity matters. The approved product has a defined population, as-needed subcutaneous autoinjector presentation, blood-pressure monitoring expectations, and monthly dose ceilings. Research-grade “PT-141” does not inherit that regulatory package. This article reviews structure and mechanism, RECONNECT phase 3 efficacy, labeled safety, and how bremelanotide sits relative to other sexual-medicine and peptide options. Educational only — not prescribing guidance and not a recommendation to use any unapproved product.

Structure and Melanocortin Biology

Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Developmentally it is closely related to melanotan II; PT-141 was the research designation for the de-amidated melanocortin analog that advanced into sexual-function programs.

The clinically relevant pharmacology is central melanocortin receptor agonism, with therapeutic effects attributed primarily to the melanocortin-4 receptor (MC4R) in hypothalamic circuits that govern appetitive sexual behavior. Early mechanistic and translational work framed PT-141 as acting through CNS melanocortin pathways rather than through peripheral vasodilatory mechanisms used by PDE5 inhibitors (Molinoff et al., 2003). That distinction is the reason bremelanotide is discussed as a desire/arousal-pathway agent rather than as a genital blood-flow drug.

Affinity is not limited to MC4R alone. Melanocortin peptides can engage multiple receptor subtypes, including MC1R, which helps explain the labeled signal for focal hyperpigmentation in a small fraction of treated patients. For clinical counseling, the useful model is: central MC4R-linked desire circuitry is the intended therapeutic axis; pigmentation and hemodynamic effects are on-target or near-target class effects that require monitoring language, not afterthoughts.

Approved Indication and What It Is Not

Per the FDA-approved Vyleesi labeling, bremelanotide is indicated for acquired, generalized HSDD in premenopausal women. The disorder is defined by low sexual desire causing marked distress or interpersonal difficulty, and the low desire should not be better explained by a coexisting medical or psychiatric condition, relationship problems, or the effects of a medication or other drug substance.

Equally important are the explicit non-indications. Labeling does not support use to enhance sexual performance, use in postmenopausal women, or use in men. That last point is clinically relevant because historical PT-141 literature and ongoing research interest in male sexual function still circulate widely online. Interest is not the same as an approved indication.

From a practice-operations standpoint, bremelanotide also differs from daily oral flibanserin (Addyi). Vyleesi is an as-needed subcutaneous injection, typically timed before anticipated sexual activity, with hard limits on dosing frequency. The product is supplied as a prefilled autoinjector rather than a multi-use research vial, which removes reconstitution ambiguity for the branded product but does not speak to compounding or research-chemical presentations. For patients asking about vial reconstitution more generally, point them to educational resources such as the reconstitution guide and peptide calculator — not as a substitute for labeled device instructions.

RECONNECT Phase 3 Efficacy

Approval rested on two identically designed, randomized, double-blind, placebo-controlled multicenter phase 3 trials (RECONNECT studies 301 and 302; NCT02333071 and NCT02338960). Premenopausal women with acquired, generalized HSDD were randomized 1:1 to as-needed subcutaneous bremelanotide 1.75 mg or placebo for 24 weeks after a screening and single-blind placebo baseline period.

Coprimary endpoints were change from baseline to end of study in:

• Female Sexual Function Index desire domain (FSFI-D)
• Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 (distress related to low desire)

In the integrated analysis reported by Kingsberg and colleagues (Obstetrics & Gynecology, 2019), bremelanotide produced a statistically significant improvement in desire (integrated mean difference +0.35 on FSFI-D versus placebo, P < .001) and a statistically significant reduction in related distress (integrated −0.33 on FSDS-DAO item 13, P < .001). Study-level results were directionally consistent (FSFI-D: +0.30 and +0.42; FSDS item 13: −0.37 and −0.29).

Safety and modified intent-to-treat populations were large by sexual-medicine standards: 1,247 women in the safety population and 1,202 in the efficacy (mITT) population across the two trials, with mean age about 39 years and predominantly U.S. enrollment. Common adverse events occurring in 10% or more of bremelanotide-treated patients in both studies included nausea, flushing, and headache. Most treatment-emergent events were mild or moderate and related to tolerability.

One interpretive nuance clinicians should keep straight: statistically significant gains on validated desire and distress instruments do not automatically mean large absolute changes on every secondary sexual-event count. Label and trial discussions have long noted that satisfying sexual event differences versus placebo were not the driver of approval; desire and distress were. That is useful framing when counseling patients who equate success solely with event frequency.

Safety, Hemodynamics, and Monitoring Framework

The safety conversation around bremelanotide is more structured than for most research peptides because labeling is explicit.

Blood pressure. Bremelanotide can cause a transient increase in blood pressure and a reduction in heart rate after each dose. These changes generally resolve within about 12 hours. Labeling contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease and advises against use in patients at high cardiovascular risk. Blood pressure should be well controlled before initiation and during treatment. In the RECONNECT program, in-clinic first-dose observation with serial BP checks was part of the protocol architecture — a reminder that hemodynamic effects are expected pharmacology, not rare idiosyncrasy.

Gastrointestinal tolerability. Nausea is the most frequent adverse effect and is a common reason for early discontinuation or rescue antiemetic discussion in real-world use of the branded product. Flushing and headache follow closely in frequency.

Focal hyperpigmentation. Because of melanocortin receptor biology (including MC1R), focal hyperpigmentation — including face, gingiva, and breasts — was reported in roughly 1% of patients receiving up to eight doses per month in the clinical program. Pigmentation changes may be slow to resolve and are part of informed-consent language.

Dose ceilings. Labeled use is one 1.75 mg subcutaneous dose as needed, no more than one dose in 24 hours, and no more than eight doses per month. Those ceilings are both efficacy-program anchors and risk-management tools for cumulative hemodynamic and pigmentary exposure.

None of the above is a substitute for reading the current full prescribing information before clinical use.

Research PT-141 vs Approved Vyleesi

Clinicians increasingly see patients who already purchased “PT-141” from research vendors, compounded pharmacies, or telehealth bundles. Several distinctions are worth making explicit in the visit:

1. Regulatory status. Vyleesi is an FDA-approved drug product for a narrow HSDD indication. Research PT-141 is not automatically the same product, process, or quality system.
2. Presentation. Branded autoinjector vs multi-dose vial changes sterility, concentration verification, and patient technique risk. Multi-use vial workflows raise the same COA and sourcing questions that apply across the peptide landscape; see also the 503A/503B compounding landscape and sourcing transparency pages.
3. Population creep. Online protocols often extend use to men, postmenopausal women, or performance enhancement. Those uses are outside the approved indication and rest on thinner or non-registrational evidence.
4. Monitoring. Approved labeling forces a blood-pressure and cardiovascular-risk conversation. Research channels often omit it.

For patients shopping providers, the directory and experts pages can help locate legitimate clinical channels rather than pure research-chemical supply chains. Price curiosity can be cross-checked against the price index, with the caveat that branded drug acquisition cost and research-vial street pricing are not interchangeable apples-to-apples figures.

Clinical Positioning

Where does bremelanotide fit in a sexual-medicine toolkit?

• It is a centrally acting peptide option for a validated HSDD phenotype in premenopausal women, not a first-line PDE5 substitute and not a general libido tonic.
• It is as-needed, which can appeal when daily oral therapy, alcohol restrictions, or adherence friction are barriers — subject to GI tolerability and BP constraints.
• It requires cardiovascular screening language that many “peptide clinic” scripts still under-emphasize.
• It is one of the cleaner teaching examples that “peptide” and “unregulated research chemical” are not synonyms. Like tesamorelin, bremelanotide shows how a peptide can move through conventional drug development into a labeled indication with phase 3 instrumentation.

For broader peptide literacy before diving into individual compounds, Peptides 101 remains the best on-site starting point.

Bottom Line

Bremelanotide (Vyleesi) is an FDA-approved melanocortin peptide agonist for acquired, generalized HSDD in premenopausal women. RECONNECT demonstrated statistically significant improvements in sexual desire and related distress versus placebo, with nausea, flushing, headache, transient blood-pressure elevation, and uncommon focal hyperpigmentation as the main safety themes. The research alias PT-141 describes the same pharmacologic family but not the same regulated product experience.

For clinicians, the value of knowing this molecule well is twofold: it is a legitimate, labeled peptide therapy in sexual medicine, and it is a frequent point of confusion when patients arrive with research vials, off-label expectations, or incomplete cardiovascular screening. Stay inside the labeled population, respect hemodynamic contraindications, and treat research-channel PT-141 as a separate risk conversation from the approved autoinjector product.

Educational content only. Not medical advice. Not a substitute for the current FDA prescribing information or individualized clinical judgment.